EVLO — Evelo Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $0.00m
- $16.69m
Annual cashflow statement for Evelo Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -56.9 | -85.5 | -93.7 | -122 | -115 |
| Depreciation | |||||
| Non-Cash Items | 6.57 | 8.25 | 10.8 | 21.2 | 20.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.16 | 3.47 | 7.76 | 2.07 | -9.67 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -47.3 | -72 | -73.1 | -96.7 | -101 |
| Capital Expenditures | -5.46 | -3.03 | -1.32 | -1.52 | -0.622 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -54.7 | 55 | 0.006 | 0.038 | 0 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -60.1 | 52 | -1.31 | -1.48 | -0.622 |
| Financing Cash Flow Items | -0.25 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 162 | 4.99 | 65.5 | 97.5 | 81.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 54.6 | -15 | -8.91 | -0.666 | -20.7 |